Clinical Trial Update: Dose-effect of SSR180575 in Diabetic Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 dose-effect study of SSR180575 in diabetic neuropathy has completed; the trial evaluated dose-response relationships in a Sanofi-sponsored study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• SSR180575 (SSR180575)

Snippet

Sponsor: Sanofi | Conditions: Diabetic Neuropathies | Phase 2 | Status: COMPLETED